Literature DB >> 21717027

A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity.

Sanjib Bhattacharyya1, Maria Gonzalez, J David Robertson, Resham Bhattacharya, Priyabrata Mukherjee.   

Abstract

A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity to (epidermal growth factor receptor) EGFR(+) cancer cells. This journal is © The Royal Society of Chemistry 2011

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21717027      PMCID： PMC3324332          DOI： 10.1039/c1cc12902c

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  19 in total

Review 1.  Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.

Authors:  A H Partridge; H J Burstein; E P Winer
Journal:  J Natl Cancer Inst Monogr       Date:  2001

Review 2.  Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology.

Authors:  Marie-Christine Daniel; Didier Astruc
Journal:  Chem Rev       Date:  2004-01       Impact factor: 60.622

Review 3.  Radiofrequency ablation of solid tumors.

Authors:  A N Mirza; B D Fornage; N Sneige; H M Kuerer; L A Newman; F C Ames; S E Singletary
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

4.  Nutritional consequences of radiotherapy.

Authors:  S S Donaldson
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

5.  [Side effects from treatment with antibiotics and chemotherapeutics].

Authors:  E Cilţea; N Precup
Journal:  Munca Sanit       Date:  1972-01

6.  Target-selective drug delivery through liposomes labeled with oligobranched neurotensin peptides.

Authors:  Chiara Falciani; Antonella Accardo; Jlenia Brunetti; Diego Tesauro; Barbara Lelli; Alessandro Pini; Luisa Bracci; Giancarlo Morelli
Journal:  ChemMedChem       Date:  2011-03-02       Impact factor: 3.466

7.  Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.

Authors:  Yi-Fan Hsu; Daniel Ajona; Leticia Corrales; Jose M Lopez-Picazo; Alfonso Gurpide; Luis M Montuenga; Ruben Pio
Journal:  Mol Cancer       Date:  2010-06-07       Impact factor: 27.401

Review 8.  Drivers of biodiagnostic development.

Authors:  David A Giljohann; Chad A Mirkin
Journal:  Nature       Date:  2009-11-26       Impact factor: 49.962

9.  Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.

Authors:  Chitta Ranjan Patra; Resham Bhattacharya; Enfeng Wang; Aaron Katarya; Julie S Lau; Shamit Dutta; Michael Muders; Shanfeng Wang; Sarah A Buhrow; Stephanie L Safgren; Michael J Yaszemski; Joel M Reid; Matthew M Ames; Priyabrata Mukherjee; Debabrata Mukhopadhyay
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

10.  Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

Authors:  Hossein Borghaei; Corey J Langer; Michael Millenson; Karen J Ruth; Samuel Litwin; Holly Tuttle; Judie Sylvester Seldomridge; Marc Rovito; David Mintzer; Roger Cohen; Joseph Treat
Journal:  J Thorac Oncol       Date:  2008-11       Impact factor: 15.609
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.